Abbott Glucose Monitor Recall
Analysis based on 10 articles · First reported Dec 03, 2025 · Last updated Dec 05, 2025
The recall of glucose monitor sensors by Abbott Laboratories is expected to negatively impact the company's stock price and reputation within the medical device industry. This event highlights regulatory risks for medical device manufacturers and could lead to increased scrutiny and potential legal actions, affecting investor confidence in the sector.
Abbott Laboratories, through its Abbott Diabetes Care division, has initiated a recall of certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose monitor sensors. The United States — Food and Drug Administration has issued a warning, urging consumers to stop using these devices due to a manufacturing issue that causes incorrect low glucose readings. This malfunction has been linked to 7 deaths worldwide and 736 serious injuries, with 57 injuries reported in the United States. The affected sensors, totaling approximately 3 million units from a single production line, pose significant health risks to people with Diabetes, potentially leading to incorrect treatment decisions such as excessive carbohydrate intake or delayed insulin doses. Abbott Laboratories has stated that the cause of the issue has been identified and resolved, and free replacements are being offered to affected customers.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard